

A systematic review and meta-analysis of thiazide-induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation?

Running Title: TIH systematic review

Authors: Jennifer Barber BMedSci^{1*}, Tricia M. McKeever PhD^{2*}, Sarah E. McDowell PhD³, Jennifer A. Clayton DM MB BS⁴, Robin E. Ferner MD MB BS³, Richard D. Gordon PhD MBBS⁵, Michael Stowasser PhD MBBS⁵, Kevin M. O'Shaughnessy DPhil BM BCh⁶, Ian P. Hall DM MB BCh¹ and Mark Glover PhD MB BChir^{1**}

Positions and addresses:

¹ Medical Student (JB), Professor of Therapeutics (IPH) and MRC Clinician Scientist (MG), Division of Therapeutics and Molecular Medicine, University of Nottingham, Nottingham, NG7 2UH, United Kingdom, ² Associate Professor and Reader, Division of Epidemiology and Public Health, University of Nottingham, Nottingham, NG5 1PB, United Kingdom, ³ Professor of Clinical Pharmacology (REF) and Post-doctoral research fellow (SMD), West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham, B18 7QH, United Kingdom, ⁴ Consultant Physician, Department of Diabetes and Endocrinology, Nottingham University Hospitals NHS Trust, Nottingham, NG7 2UH, United Kingdom, ⁵ Professor of Medicine (RDG and MS), Endocrine Hypertension Research Centre, University of Queensland School of Medicine, Brisbane, Australia, ⁶ Senior Lecturer, Clinical Pharmacology Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 2QQ, United Kingdom.

*joint first authors

****Correspondence to:** Dr M. Glover, Division of Therapeutics and Molecular Medicine, Queen's Medical Centre, Nottingham, NG7 2UH, UK.

E-mail: mark.glover@nottingham.ac.uk

Structured summary: 244 words

Body of manuscript: 3076 words

Number of Figures: 1

Number of Tables: 4

Number of online supplements: 1

1 **Structured summary**

2 **Aims:** Hyponatraemia is one of the major adverse effects of thiazide diuretics and the leading
3 cause of drug-induced hyponatraemia requiring hospital admission. We sought to review and
4 analyse all published cases of this important condition.

5 **Methods:** Ovid Medline, Embase, Web of Science and PubMed electronic databases were
6 searched to identify all relevant articles published before October 2013. A proportions meta-
7 analysis was undertaken.

8 **Results:** 102 articles were identified of which 49 were single patient case reports. Meta-analysis
9 showed that mean age was 75 (95% CI 73–77) years, 79% were women (95% CI 74–82) and
10 mean body mass index was 25 (95% CI 20–30) kg/m². Presentation with thiazide-induced
11 hyponatraemia occurred a mean of 19 (95% CI 8-30) days after starting treatment, with mean
12 trough serum sodium concentration of 116 (95% CI 113 to 120) mM and serum potassium of 3.3
13 (95% CI 3.0 to 3.5) mM. Mean urinary sodium concentration was 64 mM (95% CI 47 to 81); the
14 most frequently reported thiazides were hydrochlorothiazide, indapamide and
15 bendroflumethiazide.

16 **Conclusions:** Patients with thiazide-induced hyponatraemia were characterised by advanced age,
17 female gender, inappropriate saluresis and mild hypokalaemia. Low BMI was not found to be a
18 significant risk factor, despite previous suggestions. The time from thiazide initiation to
19 presentation with hyponatraemia suggests that the recommended practice of performing a single
20 investigation of serum biochemistry 7–14 days after thiazide initiation may be insufficient or
21 suboptimal. Further larger and more systematic studies of thiazide-induced hyponatraemia are
22 required.

23

24

25

1 **What is known about this subject**

- 2 • Thiazide/thiazide-like diuretics are amongst the top 5 most prescribed medicines in the UK and
3 one of the most widely prescribed and effective anti-hypertensive classes of medication
4 worldwide.
- 5 • Most physicians are familiar with prescribing thiazides and of their limiting side effects,
6 of which hyponatraemia is amongst the most commonly encountered and medically serious.
- 7 • Thiazide-induced hyponatraemia is the leading cause of drug-induced hyponatremia
8 requiring hospitalisation in the UK.

9 **What this study adds**

- 10 • This systematic review and meta-analysis is the first time (to our knowledge) that anyone
11 has attempted to analyse the entire published literature (1962-2013) on this common and serious
12 adverse drug effect.
- 13 • This work challenges the perception that underweight patients are those who typically
14 suffer from this side effect and, if people are sticking to the rules with serum electrolyte
15 monitoring, calls into question whether the standard UK practise of a blood test 1-2 weeks after
16 starting thiazides is optimal since the mean time to presentation with hyponatraemia occurred
17 outside (after) this monitoring period.

18
19
20
21
22
23
24
25

1 **Introduction**

2 Thiazide and thiazide-like diuretics, although they differ in chemical structure, all inhibit the
3 thiazide-sensitive sodium–chloride co-transporter, NCC, in the distal convoluted tubule of the
4 kidney [1]. Since the demonstration of their anti-hypertensive effect in 1958 [2] they have been
5 widely used in the management of hypertension, and continue to be so, notwithstanding their
6 recent and controversial demotion to step 3 in UK hypertension guidance [3,4]. Their benefits on
7 all-cause mortality are equal to those of angiotensin-converting enzyme (ACE) inhibitors and
8 calcium channel antagonists [5,6].

9 However thiazide diuretics often cause adverse effects, of which thiazide-induced
10 hyponatraemia is amongst the most clinically important [7]. Thiazide-induced hyponatraemia
11 may also represent a scientifically important paradigm of the dysregulation of sodium (and water)
12 transport within the distal nephron [8].

13 Thiazide diuretics are the most common cause of drug-induced hyponatraemia in
14 secondary care [9]. Severe thiazide-induced hyponatraemia causes debilitating symptoms such as
15 confusion, falls and seizures, and can sometimes be fatal [7]. Thiazide-induced hyponatraemia
16 necessitating hospital admission is common enough to suggest that current monitoring regimens
17 are suboptimal [9]. Importantly, the mechanism of thiazide-induced hyponatraemia is also poorly
18 understood; mean serum sodium concentration in the total treated population is virtually
19 unchanged by thiazide therapy [10], implying that thiazide-induced hyponatraemia occurs in a
20 susceptible subgroup. However this subgroup cannot be prospectively identified at present and
21 so thiazide-induced hyponatraemia is largely unpredictable at the point of thiazide initiation. We
22 therefore set out to undertake a systematic review and meta-analysis of all thiazide-induced
23 hyponatraemia reports published to date in order to summarise and reflect on current
24 understanding of this condition.

25

1 **Methods**

2 *Search strategy*

3 Medline, Embase, Web of Science and PubMed databases were searched on 1st October 2013
4 without limitation on language. The Ovid interface was used to search Medline and Embase
5 using the terms “thiazide AND hyponatr\$emia”, “thiazide-induced hyponatr\$emia” and
6 “thiazide- associated hyponatr\$emia”. Web of Science and PubMed were searched using the
7 terms “(thiazide AND (hyponatraemia OR hyponatraemia)”, “(thiazide-induced AND
8 (hyponatraemia OR hyponatraemia)”, “(thiazide-associated AND (hyponatraemia OR
9 hyponatraemia)”. Database searches were also undertaken with the term ‘thiazide’ replaced
10 alternatively by either ‘indapamide’ or ‘chlortalidone’. Articles that cited or were cited by the
11 included studies were also screened to identify any further relevant studies. Duplicated results
12 and studies containing no primary data or non-human data only were removed. The conventional
13 definition for hyponatraemia of serum sodium concentration $\leq 135\text{mM}$ was used [11,12].

14 *Data extraction*

15 Two authors (JB and MG) independently reviewed the titles, abstracts and full text of identified
16 papers. References of all full text papers were searched to identify any additional pertinent
17 papers. Disagreements were resolved by discussion. Data extraction was performed using a
18 structured template to collect information on study design (including location of study and year
19 of publication) and thiazide-induced hyponatraemia phenotype including age, sex, presenting
20 symptoms, drug history including concomitant drug use and laboratory findings. Methodological
21 quality was independently rated by two authors (JB and MG) using a modified version scale
22 developed for observational studies¹³. The range of possible scores was 0-12.

23 *Data analysis*

24 Study parameters which were reported in more than 1% of patients are presented. We excluded
25 from the analysis any measurement given qualitatively as “normal” without any indication of the

1 value itself or the reference range. For publications in which more than one patient was reported
2 a proportions meta-analysis was conducted to look at the weighted frequency of clinical
3 phenotype, drug history and laboratory findings for the combined number of papers contributing
4 to each separate analysis. A random effects model was used to determine 95% confidence
5 intervals, using the DerSimonian and Laird method to calculate weights [14]. Study
6 heterogeneity was assessed using I^2 scores. Causes of high levels of heterogeneity were explored
7 by dividing the following variables at the median level: quality score, year of publication, and
8 age of study population. Evidence for the possibility of publication bias was assessed by funnel
9 plots. Single case reports were simply summarised.

10 The presentation of the meta-analyses adhered to the Meta-analysis of Observational
11 Studies in Epidemiology (MOOSE) consensus statement [15]. All proportional analyses were
12 performed using the Stats Direct[®] statistical software package version 2.7.9 and Stata[®] version
13 12 for the meta-analyses of mean values.

14 **Results**

15 Database searches resulted in 1359 citations. After exclusion of duplicates and articles where
16 data was non-human or irrelevant to thiazide-induced hyponatraemia in adults, 102 articles
17 remained (median date of publication was 1998, range 1962-2013) and were analysed (Figure 1).
18 Of the 102 articles analysed, 49 were single case reports [16-64] (Supplementary Table 1) and
19 the remaining 52 articles ranged from 2 to 1802 patients [65-117] (Supplementary Table 2). 4
20 papers were also removed because the same study population was already represented in the 102
21 articles included in the review [118-121].

22 The mean value for quality score was 4.0 (range 1–8) for studies included in the meta-
23 analysis and 3.2 for single case reports (range 1–6). The main reasons for low quality scores
24 were a lack of clearly stated inclusion and exclusion criteria, absence of documented patient
25 consent and/or ethical approval, a lack of inclusion of patient perception, a lack of clarity

1 regarding the name, dose and duration of thiazide therapy and whether thiazide-induced
2 hyponatraemia patients represented a consecutive series treated consistently by the same
3 physician(s) or at a single institution.

4 **FIGURE 1 HERE**

5 *Meta-analysis Findings*

6 *Clinical Characteristics*

7 Patients with thiazide-induced hyponatraemia had a mean age of 75 years (pooled estimate, 95%
8 CI 73 to 77 years, based on 36 studies and 2840 patients, Figure S1), 79% were women (95% CI
9 74–82%, $I^2 = 65%$, based on 43 studies and 3269 patients, Figure S2) and mean body mass index
10 was 25 kg/m² (pooled estimate, 95% CI 20–30 kg/m², $I^2 = 100%$, based on 2 studies and 2025
11 patients, Figure S3). Thiazide-induced hyponatraemia was first detected a mean of 19 days
12 (pooled estimate, 95% CI 8-30 days, $I^2 = 97%$, based on 19 studies and 446 patients, Figure S4)
13 after starting thiazide treatment (Table 1). Sensitivity analysis by removal of studies with delay
14 to thiazide-induced hyponatremia >100 days also showed the time to detection was greater than
15 the standard 7-14 day serum electrolyte monitoring period (17 days, 95% CI 6 to 28 days, based
16 on 14 studies with 415 patients). The levels of heterogeneity were explored by quality score, year
17 of publication and age of patients; however none of these factors could explain the high levels of
18 heterogeneity (Table S3).

19 Clinical characteristics of patients with thiazide-induced hyponatraemia are presented in
20 Table 2 (Meta-analyses graphs Figures S5 to S14). The most frequently reported symptoms at
21 presentation were: falls (48%, 95% CI 20 to 77%, $I^2 = 84%$, based on 5 studies and 252 patients);
22 fatigue (46%, 95% CI 21 to 72%, $I^2 = 92%$, based on 8 studies and 333 patients); weakness (45%,
23 95% CI 32 to 58%, $I^2 = 49%$, based on 14 studies and 247 patients); confusion (44%, 95% CI 33
24 to 56%, $I^2 = 85%$, based on 22 studies and 710 patients); nausea (36%, 95% CI 24 to 48%, $I^2 =$
25 76%, based on 14 studies and 405 patients); and vomiting (35%, 95% CI 25 to 45%, $I^2 = 68%$,

1 based on 13 studies and 549 patients). Also reported were other neurological symptoms,
2 dizziness, unconsciousness and seizures (Table 2). Analyses of clinical characteristics revealed
3 substantial heterogeneity between studies which were not explained by quality score, year of
4 publication or age of patient (Table S4).

5

6 *Co-morbidities*

7 The most commonly reported comorbidities included cardiovascular disease (49%, 95%
8 CI 33 to 65%, $I^2 = 72%$, based on 12 studies and 284 patients, Figures S15) and diabetes mellitus
9 (27%, 95% CI 14 to 42%, $I^2 = 99%$, based on 9 studies and 3029 patients, Figure S16). Analyses
10 of comorbidities revealed substantial heterogeneity between studies which was not explained by
11 quality score, year of publication or age of patient (Table S3). A single study of 1802 patients
12 reported the prevalence of gastro-oesophageal reflux disease (24%), hyperlipidemia (47%) and
13 urinary tract infection (24%) [104].

14

15 *Medication history*

16 Thiazide-induced hyponatraemia was reported in association with a wide range of
17 thiazide/thiazide-like drugs (Table 3, meta-analyses graphs in Figures S17 to S22). By far the
18 most frequently implicated was hydrochlorothiazide either alone (68%, 95% CI 52 to 82%, $I^2 =$
19 97%, based on 19 studies and 2583 patients) or in combination with amiloride (as Moduretic[®],
20 73%, 95% CI 57 to 87%, $I^2 = 92%$, based on 19 studies and 633 patients) or triamterene (as
21 Dyazide[®], 18%, 95% CI 8 to 32%, $I^2 = 36%$, based on 3 studies and 59 patients). Other
22 thiazide/thiazide-like drugs implicated were indapamide, bendroflumethiazide (bendrofluazide),
23 and chlortalidone. Analyses of which individual thiazide/thiazide-like drugs were associated with
24 hyponatraemia revealed high levels of heterogeneity between studies and this was not explained
25 by quality score, year of publication or age of patient (Table S4).

1 Details of concurrent non-thiazide medication in patients with thiazide-induced
2 hyponatraemia are presented in Table 3 (meta-analyses graphs Figures S23 to S28). Commonly
3 reported non-thiazide co-prescriptions were angiotensin II receptor antagonists (59%, 95% CI 0
4 to 96%, $I^2 = 99%$, based on 3 studies and 1844 patients), Angiotensin Converting Enzyme (ACE)
5 inhibitors (51%, 95% CI 27 to 75%, $I^2 = 96%$, based on 5 studies and 2000 patients), non-
6 thiazide diuretics (e.g. loop- and potassium sparing- diuretics) (58%, 95% CI 19 to 91%, $I^2 =$
7 86%, based on 5 studies and 1815 patients), Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
8 (33%, 95% CI 18 to 49%, $I^2 = 89%$, based on 6 studies and 2036 patients), and anti-depressants
9 (32%, 95% CI 19 to 47%, $I^2 = 68%$, based on 6 studies and 1882 patients). While Selective
10 Serotonin Reuptake Inhibitors (SSRIs) are associated with hyponatraemia, there was insufficient
11 data to determine what proportion of the anti-depressant medication reported were SSRIs.
12 Analyses of polypharmacy demonstrated high levels of heterogeneity between studies, which
13 was not explained by quality score, year of publication or age of patient (Table S5).

14 *Laboratory Characteristics*

15 As shown in Table 4 (Figures S29 to S34), thiazide-induced hyponatraemia patients had severe
16 hyponatraemia, with a mean trough serum sodium concentration of 116 mM (95% CI 113 to 120
17 mM, $I^2=99%$, based on 37 studies and 1042 patients), mild hypokalaemia, with serum potassium
18 3.3 mM (95% CI 3.0 to 3.5 mM, $I^2=97%$, based on 28 studies and 902 patients), and normal
19 renal function, serum creatinine 76.8 $\mu\text{mol/L}$ (95% CI 64.1 to 89.4 $\mu\text{mol/L}$, $I^2=99%$, based on 17
20 studies and 504 patients). Corresponding urinary electrolyte data indicates inappropriate
21 saliuresis, with urinary sodium concentration 64 mM (95% CI 47 to 81 mM, $I^2=94%$, based on
22 13 studies and 98 patients). Mean serum and urine osmolalities were 240 mOsm/kg (95% CI 236
23 to 245 mOsm/kg, $I^2=80%$, based on 11 studies and 229 patients) and 402 mOsm/kg (95% CI 370
24 to 432 mOsm/kg, $I^2=81%$, based on 14 studies and 322 patients) respectively. In most analyses

1 of laboratory characteristics there were high levels of heterogeneity between studies, which were
2 not explained by quality score, year of publication or age of patient (Table S6).

3 **Discussion**

4 We present, to our knowledge, the first systematic review and meta-analysis of the observational
5 literature regarding the clinical and laboratory characteristics of thiazide-induced hyponatraemia.
6 Patients with thiazide-induced hyponatraemia were characterised by advanced age, female
7 gender, inappropriate saluresis and mild hypokalaemia. In addition, patients had normal BMI, in
8 contrast to suggestions that such patients tend to be underweight [7].

9 The most notable finding is of the delay from thiazide initiation to diagnosis of thiazide-
10 induced hyponatraemia which averaged 19 days (95% CI 8 to 30 days, Figure S4). Current best
11 practice is to measure serum biochemistry 1–2 weeks after thiazide initiation [122]. Our data
12 suggest that either best practice is not followed [123], or that testing at 1–2 weeks fails to detect
13 some patients who go on to develop thiazide-induced hyponatraemia [9] in which case changes
14 in monitoring schedules might improve current practice. Without data reporting either the
15 frequency of routine biochemical monitoring or the levels of serum sodium from such
16 monitoring it is not possible to confidently recommend what the optimal timing of a single
17 electrolyte check should be or whether there would be merit in performing a second electrolyte
18 measurement after the initial fortnight following thiazide initiation, e.g. at 3–4 weeks. Since in a
19 few cases, severe hyponatraemia developed many months or even years after thiazide initiation,
20 it would be prudent to measure serum electrolyte concentrations whenever patients treated with
21 thiazides develop symptoms suggestive of hyponatraemia, regardless of the duration of thiazide
22 therapy.

23 Mild hypokalaemia accompanying thiazide-induced hyponatraemia may occur simply as
24 a consequence of excessive saluresis and consequent electrogenic exchange of potassium for
25 sodium in the collecting duct. Additional mechanisms may also contribute; for example (1)

1 aldosterone activation of the distal nephron, as is to be expected and not uncommonly seen with
2 thiazide-induced hypokalaemia and hyperaldosteronism [124], or (2) With No lysine protein
3 Kinase (WNK) regulation of the renal outer-medullary potassium channel (ROMK) in the
4 collecting duct and the thiazide-sensitive sodium chloride cotransporter (NCC) in the distal
5 convoluted tubule as has been proposed for the hyperkalemia seen in Gordon syndrome [125], a
6 Mendelian disorder of thiazide-responsive hypertension and metabolic acidosis.

7 Hyperlipidemia was the most common comorbidity. Whilst severe hyperlipidemia is a
8 well-recognised cause of pseudo-hyponatraemia in older studies that relied on methods such as
9 flame photometry to measure serum sodium concentration, most dyslipidemia is very unlikely to
10 affect modern assay methods. The second most common comorbidity was diabetes mellitus.
11 Plasma glucose concentration was reported infrequently and it is possible that hyperglycemia
12 could have contributed to hyponatraemia in some cases. Since for the vast majority of patients
13 reported the indication for thiazide prescription was hypertension and presentation was with
14 symptomatic hyponatraemia it is not possible to make meaningful conclusions either regarding
15 thiazide-induced hyponatraemia when thiazide prescriptions were for indications other than
16 hypertension or the differences between symptomatic versus non-symptomatic patients.

17 Several of the medicines most commonly co-prescribed with thiazides among studies
18 included in this meta-analysis, such as ACE inhibitors, AT₁ receptor antagonists, NSAIDs and
19 some anti-depressants, are associated with hyponatraemia through well-described mechanisms.
20 This raises the possibility that some cases of apparent thiazide-induced hyponatraemia could
21 result from pharmacodynamic interactions of these drugs with thiazides. It was also notable that
22 hypokalaemia was seen despite the frequency of concurrent therapy with ACE inhibitors, AT₁
23 receptor antagonists and potassium supplements.

24 The finding of a normal serum creatinine concentration is unexpected in such an elderly
25 cohort at higher than average vascular risk, many of whom also took ACE inhibitors, ARBs

1 and/or NSAIDs. BMI was normal, so low muscle mass is unlikely to predominantly account for
2 this raising the possibility of a dilutional component to the observed serum creatinine
3 concentrations. Thus in addition to inappropriate saluresis and inappropriately high urinary
4 osmolarity, inappropriately low serum creatinine concentration is consistent with volume
5 expansion and the overall phenotype could therefore be alternatively described as having much
6 in common with thiazide-induced Syndrome of Inappropriate Anti-Diuretic Hormone secretion
7 (SIADH) [126].

8 There are significant limitations to this systematic review. Included studies were very
9 heterogenous with respect to the detail of their description, specific parameters recorded and
10 laboratory methods used and this did not appear to be explained by either individual study
11 quality, median date of publication, or whether the study pertained to a particular ‘specialist
12 group’. One possible explanation for the high level of heterogeneity found in the analyses may
13 be the local prescribing habits of the areas in which these often small studies were undertaken
14 given that case series usually focused on small numbers from a single institution over a relatively
15 short project interval. Case reports were excluded from our meta-analysis but we accept that a
16 case report may describe unusual but important presenting clinical and laboratory characteristics
17 of patients with thiazide-induced hyponatraemia. For this reason we have presented a summary
18 of the case report data alongside that for the meta-analysis in Tables 1-4. It is also possible that
19 some publications were not identified by our search of the four principal databases used,
20 however the extensive searches and the searching of references list limits the possibility of many
21 missing articles. Publication bias is still a possibility; however none of the funnel plots from the
22 meta-analyses indicated that this was a problem. The vast majority of reports detailed patients
23 who had been admitted to hospitals with symptomatic hyponatraemia and it is therefore likely
24 that asymptomatic and non-hospitalised patients with thiazide-induced hyponatraemia are
25 underrepresented.

1 There are also specific issues with respect to the phenotypic parameters measured by
2 observational studies; advanced age is confounded by the prescribing of thiazides to older
3 patients and the over-representation of females may be confounded by the shorter life expectancy
4 of males. Although oestrogens do affect sodium transport via the thiazide-sensitive NCC [127],
5 the age of the cohort reported would put the vast majority well beyond the menopause.
6 Alternatively perhaps the sex distribution is pathophysiologically significant; in the age category
7 70–74 years for the UK in the median year of publication (1998), females constituted only 55%
8 of the population [128] and yet 73% of thiazide-induced hyponatraemia patients in our meta-
9 analysis were female.

10 It is not possible to draw meaningful conclusions regarding the prevalence of thiazide-
11 induced hyponatraemia with respect to individual thiazide drugs from the available data, apart
12 from observing that thiazide-induced hyponatraemia is reported with many thiazides including
13 indapamide and chlortalidone, the two currently recommended thiazide-like diuretics for
14 hypertension in the UK [4].

15 The detailed study of the phenotype and pathophysiology of patients with thiazide-
16 induced hyponatraemia has the potential not only to improve clinical care of patients prescribed
17 thiazides but also potentially to uncover novel pathophysiological insights into salt and water
18 handling in the kidney which are clearly disturbed in these individuals. In the absence of a
19 prospective trial exposing thousands of patients to thiazides with extensive follow up (which is
20 unlikely due to prohibitive expense and limited interest from pharmaceutical companies given
21 the very old non-patented nature of thiazides), larger scale prospective observational studies with
22 detailed phenotyping of thiazide-induced hyponatraemia patients is required. Such a study is
23 already taking place across several acute hospitals throughout the UK (NIHR CRN portfolio
24 identity 10795).

1 In conclusion this study found that patients with thiazide-induced hyponatraemia were
2 characterised by advanced age, female gender, inappropriate saluresis and mild hypokalaemia.
3 Such patients had a normal BMI and were diagnosed later than the usual serum electrolyte
4 monitoring interval of 7-14 days after thiazide commencement. Until further studies determine
5 the optimal timing and frequency of electrolyte monitoring regimens it would seem prudent to be
6 mindful of the development of hyponatraemia outside of the first fortnight of thiazide therapy.

7

8 **Acknowledgements and competing interests declarations**

9 This work was supported by a Clinician Scientist award from the Medical Research
10 council (MG) and an Academy of Medical Sciences starter grant for Clinical Lecturers (MG).

11 All authors have completed the ICMJE uniform disclosure form at
12 http://www.icmje.org/coi_disclosure.pdf and declare: Dr. Glover reports a Clinician Scientist
13 grant from Medical Research Council and a starter grant for clinical lecturers from the Academy
14 of Medical Sciences, for the submitted work. Dr Glover and Dr Clayton report a grant from
15 Otsuka, outside the submitted work in the previous three years. Professor Ferner reports
16 providing expert medico-legal evidence on adverse drug reactions. There are no other
17 relationships or activities that could appear to have influenced the submitted work. None of the
18 funders had any role in study design; in the collection, analysis, and interpretation of data; in the
19 writing of the report; or in the decision to submit the article for publication.

20 **References**

21 1. Glover M, Mercier Zuber A, O'Shaughnessy KM. Hypertension, Dietary Salt Intake, and the
22 Role of the Thiazide-Sensitive Sodium Chloride Transporter NCCT. *Cardiovasc Ther*
23 2011; 29: 68-76.

- 1 2. Freis ED, Wanko A, Wilson IM, Parrish AE. Treatment of essential hypertension with
2 chlorothiazide (diuril): Its use alone and combined with other antihypertensive agents.
3 JAMA 1958; 166: 137-140.
- 4 3. Brown MJ. The choice of diuretic in hypertension: saving the baby from the bathwater. *Heart*
5 2011; 97: 1547-1551.
- 6 4. NICE. Hypertension: clinical management of primary hypertension in adults. Clinical
7 guideline CG127 2011. Available at <http://guidance.nice.org.uk/CG127>. Accessed May 1
8 2014
- 9 5. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of
10 cardiovascular disease: meta-analysis of 147 randomised trials in the context of
11 expectations from prospective epidemiological studies. *BMJ* 2009; 338: b1665.
- 12 6. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major
13 outcomes in high-risk hypertensive patients randomized to angiotensin converting
14 enzyme inhibitor or calcium channel blocker vs diuretic. *JAMA* 2002; 288: 2981-2997.
- 15 7. Glover M, Clayton J. Thiazide-Induced Hyponatraemia: Epidemiology and Clues to
16 Pathogenesis. *Cardiovasc Ther* 2012; 30: e219-26.
- 17 8. Glover M, O'Shaughnessy KM. Molecular insights from dysregulation of the thiazide-
18 sensitive WNK/SPAK/NCC pathway in the kidney: Gordon syndrome and Thiazide-
19 Induced Hyponatraemia. *Clin Exp Pharmacol Physiol* 2013; 40: 876-84.
- 20 9. Clayton JA, Le Jeune IR, Hall IP. Severe hyponatraemia in medical in-patients: aetiology,
21 assessment and outcome. *Q J Med* 2006; 99: 505-511.
- 22 10. Clayton JA, Rodgers S, Blackey J, Avery A, Hall IP. Thiazide diuretic prescription and
23 electrolyte abnormalities in primary care. *Br J Clin Pharmacol* 2005; 61: 87-95.
- 24 11. Reynolds RM, Seckl JR. Hyponatraemia for the clinical endocrinologist. *Clin Endocrinol*
25 (Oxf) 2005; 63: 366-374.

- 1 12. Clinical practice guideline on diagnosis and treatment of hyponatraemia. [published online
2 ahead of print April 9, 2014]. *Nephrol Dial Transplant*. doi: 10.1093/ndt/gfu040.
- 3 13. Albrecht J, Werth VP, Bigby M. The role of case reports in evidence-based practice, with
4 suggestions for improving their reporting. *J Am Acad Dermatol* 2009; 60: 412-418.
- 5 14. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; 7: 177-88.
- 6 15. Stroup DF, Berlin JA, Morton SC. Meta-analysis of observational studies in epidemiology: A
7 proposal for reporting. *JAMA* 2000; 283: 2008-2012.
- 8 16. Achinger SG, Moritz ML, Ayus JC. Dysnatremias: Why Are Patients Still Dying? *South*
9 *Med J* 2006; 99: 353-62.
- 10 17. Adroque HJ, Madias NE. Hyponatraemia. *N Engl J Med* 2000; 342: 1581-1589.
- 11 18. Al-Salman J, Pursell R. Hyponatremic encephalopathy induced by Thiazide. *West J Med*
12 2001; 175: 87.
- 13 19. Ayus JC, Levine R, Arieff A. Fatal dysnatraemia caused by elective colonoscopy. *BMJ* 2003;
14 326: 382.
- 15 20. Benfield GFA, Haffner C, Harris P, Stableforth DE. Dilutional hyponatraemia masquerading
16 as subarachnoid haemorrhage in patient on hydrochlorothiazide/amiloride/ timolol
17 combined drug. *Lancet* 1986; 328: 341.
- 18 21. Berl T, Rastegar A. A Patient With Severe Hyponatraemia and Hypokalaemia: Osmotic
19 Demyelination Following Potassium Repletion. *Am J Kidney Dis* 2010; 55: 742-748.
- 20 22. Cakir M. Significant hyperkalemia and hyponatraemia secondary to
21 telmisartan/hydrochlorothiazide treatment. *Blood Pressure* 2010; 19: 380-382.
- 22 23. Coler C, Hoffman MD, Towle G, Hew-Butler T. Hyponatraemia in an 85-Year-Old Hiker:
23 When Depletion Plus Dilution Produces Delirium. *Wilderness Environ Med* 2012; 23:
24 153-157.

- 1 24. Collier JG, Webb DJ. Severe thiazide-induced hyponatraemia during treatment with enalapril.
2 Postgrad Med J 1987; 63: 1105-1106.
- 3 25. Cundy T, Trafford JA. Efficacy of peritoneal dialysis in severe thiazide-induced
4 hyponatraemia. Postgrad Med J 1981; 57: 734-735.
- 5 26. Eastell R, Edmonds CJ. Hyponatraemia associated with trimethoprim and a diuretic. BMJ
6 (Clin Res Ed) 1984; 289: 1658-1659.
- 7 27. Fadel S, Karmali R, Cogan E. Safety of furosemide administration in an elderly woman
8 recovered from thiazide-induced hyponatraemia. Eur J Intern Med 2009; 20: 30-34.
- 9 28. Fuisz RE, Lauler DP, Cohen P. Diuretic-induced hyponatraemia and sustained antidiuresis.
10 Am J Med 1962; 33: 783-791.
- 11 29. Gardner LB, Preston RA. University of Miami Division of Clinical Pharmacology
12 Therapeutic Rounds: the water-intolerant patient and perioperative hyponatraemia. Am J
13 Ther 2000; 7: 23-30.
- 14 30. Ghose RR. Reset osmostat after diuretic treatment. BMJ 1977; 2: 1063.
- 15 31. Gossain VV, Hagen GA, Sugawara M. Drug-induced hyponatraemia in psychogenic
16 polydipsia. Postgrad Med J 1976; 52: 720-722.
- 17 32. Hamburger S, Koprivica B, Ellerbeck E, Covinsky JO. Thiazide-induced syndrome of
18 inappropriate secretion of antidiuretic hormone: Time course of resolution. JAMA 1981;
19 246: 1235-1236.
- 20 33. Handler J. Well Tolerated Spironolactone-Related Hyponatraemia. J Clin Hypertens
21 (Greenwich) 2008; 10: 317-21.
- 22 34. Husby S, Marthedal NJ. Hyponatraemia due to a thiazide diuretic. A case report. Acta Med
23 Scand 1981; 210: 523-524.
- 24 35. Hussain I, Jan A, Doherty J, Hickey P. Severe symptomatic hyponatraemia. Ir Med J 2011;
25 104: 285-286.

- 1 36. Jen H-L, Tsai S-H, Wang C-J, Yin W-H, Young MS. Acute hyponatraemia and
2 hypokalaemia associated with indapamide - A case report. *Acta Cardiol Sin* 2002; 18:
3 206-210.
- 4 37. Johnson E, Wright F. Thiazide-Induced Hyponatraemia. *South Med J* 1983; 76: 1363-7.
- 5 38. Karp BI, Lauren R. Pontine and extrapontine myelinolysis: a neurologic disorder following
6 rapid correction of hyponatraemia. *Medicine (Baltimore)* 1993; 72: 359-373.
- 7 39. Kennedy RM, Earley LE. Profound Hyponatraemia Resulting from a Thiazide-Induced
8 Decrease in Urinary Diluting Capacity in a Patient with Primary Polydipsia. *N Engl J*
9 *Med* 1970; 282: 1185-1186.
- 10 40. Kone B, Gimenez L, Watson AJ. Thiazide-Induced Hyponatraemia. *South Med J* 1986; 79:
11 1456-7.
- 12 41. Lin SH, Chau T, Wu CC, Yang SS. Osmotic Demyelination Syndrome after Correction of
13 Chronic Hyponatraemia with Normal Saline. *Am J Med Sci* 2002; 323: 259-62.
- 14 42. Luft FC. Salt and water metabolism in clinical daily routine. *Internist* 1998; 39: 804-809.
- 15 43. Lundbom N, Laurila O, Laurila S. Central pontine myelinolysis after correction of chronic
16 hyponatraemia. *Lancet* 1993; 342: 247-248.
- 17 44. Mataverde AQ, Abbasi AA, Hossain Z, Bissell GW. Hydrochlorothiazide-induced water
18 intoxication in myxedema. *JAMA* 1974; 230: 1014-1015.
- 19 45. Menashe G, Borer A, Gilad J, Horowitz J. Rhabdomyolysis after correction of severe
20 hyponatraemia. *Am J Emerg Med* 2000; 18: 229-230.
- 21 46. Meuleman JR. Walking the tightrope: the challenge of elder care. *J Am Geriatr Soc* 1996; 44:
22 1466-1468.
- 23 47. Miyasaka M, Hamaki T, Kami M, Hamabe Y. A patient with heatstroke associated with
24 consciousness disturbance secondary to hyponatraemia: a case report. *J Med Case Rep*
25 2013; 7: 62.

- 1 48. Mok N-S, Tong C-K, Yuen H-C. Concomitant-acquired Long QT and Brugada syndromes
2 associated with indapamide-induced hypokalemia and hyponatremia. *Pacing Clin*
3 *Electrophysiol* 2008; 31:772-5.
- 4 49. Mouallem M, Brif I, Mayan H, Farfel Z. Prolonged therapy by the combination of
5 furosemide and Thiazide in refractory heart failure and other fluid retaining conditions.
6 *Int J Cardiol* 1995; 50: 89-94.
- 7 50. Mount DB, Krahn TA. Hyponatraemia: Case Vignettes. *Sem Nephrol* 2009; 29: 300-317.
- 8 51. Moussa NA, Osman AR, Yahya TM. Acute Hyponatremic Encephalopathy After a
9 Cerebrovascular Accident. *Am J Med Sci* 1998; 316: 56-59.
- 10 52. Mozes B, Pines A, Werner D, Olchovsky D, Lieberman P, Frankl O. Thiazide-Induced
11 Hyponatraemia: An Unusual Neurologic Course. *South Med J* 1986; 79: 629-31.
- 12 53. Onozaki A, Suzuki H, Imamura N, Katoh T, Watanabe T. Congenital nephrogenic diabetes
13 insipidus with marked hyponatraemia. *Clin Exp Nephrol* 2001; 5: 265-267.
- 14 54. Orija IB, Cohen SB. An elderly woman with drug-induced coma in winter. *Cleve Clin J Med*
15 2001; 68: 25-32.
- 16 55. Ponte CD. A suspected case of thiazide-induced hyponatraemia. *Drug Intell Clin Pharm* 1982;
17 16: 699-700.
- 18 56. Ranta A, Wooten GF. Hyponatraemia due to an Additive Effect of Carbamazepine and
19 Thiazide Diuretics. *Epilepsia* 2004; 45: 879.
- 20 57. Roberts CJ, Channer KS, Bungay D. Hyponatraemia induced by a combination of
21 hydrochlorothiazide and triamterene. *BMJ (Clin Res Ed)* 1984; 288: 1962.
- 22 58. Shah PJ, Greenberg WM. Water intoxication precipitated by thiazide diuretics in polydipsic
23 psychiatric patients. *Am J Psychiatry* 1991; 148: 1424-1425.
- 24 59. Sterns RH, Hix JK, Silver S. Treating Profound Hyponatraemia: A Strategy for Controlled
25 Correction. *Am J Kidney Dis* 2010; 56: 774-779.

- 1 60. Strykers PH, Stern RS, Morse BM. Hyponatraemia induced by a combination of amiloride
2 and hydrochlorothiazide. JAMA 1984; 252: 389.
- 3 61. Van Assen S, Mudde AH. Severe hyponatraemia in an amiloride/hydrochlorothiazide-treated
4 patient. Neth J Med 1999; 54: 108-113.
- 5 62. Wierzbicki AS, Ball SG, Singh NK. Profound hyponatraemia following an idiosyncratic
6 reaction to diuretics. Int J Clin Pract 1998; 52: 278-279.
- 7 63. Wijnen H, Mesker P, Rikkert MO. Hyponatraemia caused by thiazide diuretics: be aware of
8 drug combinations which enhance this effect. Ned Tijdschr Geneesk 2002; 146: 2109-
9 2110.
- 10 64. Yap HY, Lau CP. Hyponatraemic encephalopathy complicating thiazide reserpine
11 preparation. Postgrad Med J 1992; 68: 149-150.
- 12 65. Aaseth JA, Tangen MK, Beitnes JO. Hyponatremic emergency - A serious side effect of
13 thiazide treatment in the elderly. Tidsskrift for den Norske Laegeforening 2001; 121: 921-
14 923.
- 15 66. Adams KR, Martin JA. Electrolyte disorders in the elderly. Drugs Aging 1991; 1: 254-265.
- 16 67. Al Qahtani M, Alshahrani A, Alskaini A, Abukhalid N, Al Johani N, Al Ammari M et al.
17 Prevalence of hyponatraemia among patients who used indapamide and
18 hydrochlorothiazide: a single center retrospective study. Saudi J Kidney Dis Transpl
19 2013; 24: 281-285.
- 20 68. Ambrosi P, Villani P, Bouvenot G. Hyponatraemia in elderly patients treated with thiazide
21 diuretics and incited to drink abundantly during the heat wave. Presse Med 2004; 33:
22 535-536.
- 23 69. Ashraf N, Locksley R, Arieff AI. Thiazide-induced hyponatraemia associated with death or
24 neurologic damage in outpatients. Am J Med 1981; 70: 1163-1168.

- 1 70. Bain PG, Egner W, Walker PR. Thiazide-induced dilutional hyponatraemia masquerading as
2 subarachnoid haemorrhage. *Lancet* 1986; 328: 634.
- 3 71. Bayer AJ, Farag R, Browne S, Pathy MS. Plasma electrolytes in elderly patients taking fixed
4 combination diuretics. *Postgrad Med J* 1986; 62: 159-162.
- 5 72. Bissram M, Scott FD, Liu L, Rosner MH. Risk factors for symptomatic hyponatraemia: the
6 role of pre-existing asymptomatic hyponatraemia. *Int Med J* 2007; 37: 149-155.
- 7 73. Booker JA. Severe symptomatic hyponatraemia in elderly outpatients: the role of thiazide
8 therapy and stress. *J Am Geriatr Soc* 1984; 32: 108-113.
- 9 74. Canning G, McKillop G, Slater SD. Dilutional hyponatraemia due to hydrochlorothiazide
10 plus amiloride (Moduretic): not to be mistaken for the syndrome of inappropriate
11 secretion of antidiuretic hormone (SIADH). *Br J Clin Pract* 1988; 42: 41-42.
- 12 75. Chapman MD, Hanrahan R, McEwen J, Marley JE. Hyponatraemia and hypokalaemia due to
13 indapamide. *Med J Aust* 2002; 176: 219-221.
- 14 76. Chow KM, Kwan BC, Szeto CC. Clinical studies of thiazide-induced hyponatraemia. *J Natl*
15 *Med Assoc* 2004; 96: 1305-1308.
- 16 77. Clayton JA, Rodgers S, Blakey J, Avery A, Hall IP. Thiazide diuretic prescription and
17 electrolyte abnormalities in primary care. *Br J Clin Pharmacol* 2006; 61: 87-95.
- 18 78. Coenraad MJ, Meinders AE, Vandenbroucke JP, Fr+lich M, Taal JCW, Bolk JH. Causes of
19 hyponatraemia in the Departments of Internal Medicine and Neurosurgery. *Eur J Intern*
20 *Med* 2003; 14: 302-309.
- 21 79. Cogan E, Abramow M. Diuretic-induced hyponatraemia in elderly hypertensive women.
22 *Lancet* 1983; 322: 1249.
- 23 80. Donaldson M. Combination diuretics in the elderly. *Med J Aust* 1983; 1: 106.
- 24 81. Fenske W1, Störk S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in
25 the Differential Diagnosis of Hyponatraemia. *J Clin Endocrinol Metab* 2009; 94: 123-9.

- 1 82. Fichman MP, Vorherr H, Kleeman C, Telfer N. Diuretic-Induced Hyponatraemia. *Ann Int*
2 *Med* 1971; 75: 853-863.
- 3 83. Furlanos S, Greenberg P. Managing drug-induced hyponatraemia in adults. *Australian*
4 *Prescriber* 2003; 23: 114-117.
- 5 84. Frenkel W, Deen P, Levi M, van den Born BJ. Determinants of Thiazide-Induced
6 Hyponatraemia in the Elderly. *J Hypertens* 2010; 28: e545.
- 7 85. Friedman E, Shadel M, Halkin H, Farfel Z. Thiazide-induced hyponatraemia. Reproducibility
8 by single dose rechallenge and an analysis of pathogenesis. *Ann Int Med* 1989; 110: 24-
9 30.
- 10 86. Ghose RR. Letter: Hyponatraemia and diuretics. *Lancet* 1975; 1: 587-589.
- 11 87. Hajjar I, Graves JW. Hyponatraemia in Older Women. *J Clin Hypertens* 2004; 6: 37-39.
- 12 88. Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatraemia in hospitalized
13 patients: treatment-related risk factors and inadequate management. *Nephrol*
14 *DialTransplant* 2006; 21: 70-76.
- 15 89. Hung TY, Ho DD, So HM, Lo MW, Yeung VTF. Life-threatening diuretic-induced
16 hyponatraemia: a review of seven patients. *Hong Kong Practitioner* 2002; 24: 337-343.
- 17 90. Hwang KS, Kim GH. Thiazide-induced hyponatraemia. *Electrolyte Blood Press* 2010; 8: 51-
18 57.
- 19 91. Johnson C, Webb L, Daley J, Spathis GS. Hyponatraemia and Moduretic-grand mal-seizures:
20 a review. *J Royal Soc Med* 1989; 82: 479-83.
- 21 92. Jolobe OMP. Diuretic-induced hyponatraemia in elderly hypertensive women. *J Hum*
22 *Hypertens* 2003; 17: 151.
- 23 93. Kalksma R, Leemhuis MP. Hyponatraemia caused by thiazide diuretics: Be aware of drug
24 combinations which enhance this effect. *Ned Tijdschr Geneesk* 2002; 146: 1521-1525.

- 1 94. Kinoshita H, Kobayashi K, Yaguramaki T, Yasuda M, Fujiki K, Tomiyama J et al. Losartan
2 potassium/hydrochlorothiazide and hyponatraemia: Case series of 40 patients. *Hum Exp*
3 *Toxicol* 2011; 30: 1409-1414.
- 4 95. Mackay M. Hyponatraemia and diuretics. *N Z Med J* 1983; 96: 635.
- 5 96. Malin JW, Kolstad K, Hozack WJ, Rothman RH. Thiazide-induced hyponatraemia in the
6 postoperative total joint replacement patient. *Orthopedics* 1997; 20: 681-683.
- 7 97. Mathew TH, Boyd IW, Rohan AP. Hyponatraemia due to the combination of
8 hydrochlorothiazide and amiloride (Moduretic): Australian spontaneous reports 1977-
9 1988. *Med J Aust* 1990; 152: 308-309.
- 10 98. McDowell SE, Coleman JJ, Evans SJW, Gill PS, Ferner RE. Laboratory monitoring and
11 adverse patient outcomes with antihypertensive therapy in primary care.
12 *Pharmacoepidem Drug Safe* 2010; 19: 482-489.
- 13 99. Mouallem M, Friedman E, Shemesh Y, Mayan H, Pauzner R, Farfel Z. Cardiac conduction
14 defects associated with hyponatraemia. *Clin Cardiol* 1991; 14: 165-168.
- 15 100. Musch W, Decaux G. Utility and limitations of biochemical parameters in the evaluation of
16 hyponatraemia in the elderly. *Int Urol Nephrol* 2001; 32: 475-493.
- 17 101. Oles KS, Denham JW. Hyponatraemia Induced by Thiazide-like Diuretics in the Elderly.
18 *South Med J* 1984; 77: 1314-5.
- 19 102. Pinnock CA. Hyponatraemia associated with hydrochlorothiazide treatment. *BMJ* 1978; 1:
20 48.
- 21 103. Rask E, Olsson T, Hagg E, Anderson P, Svensson I. Hyponatraemia caused by diuretics in
22 elderly women. Risk of adverse effects. Be careful with indications. *Lakartidningen*.
23 1996; 83: 4269-4270.
- 24 104. Rastogi D, Pelter MA, Deamer RL. Evaluations of Hospitalizations Associated With
25 Thiazide-Associated Hyponatraemia. *J Clin Hypertens* 2012; 14: 158-164.

- 1 105. Rodenburg EM, Hoorn EJ, Ruiter R, Lous JJ, Hofman A, Uitterlinden AG et al. Thiazide-
2 Associated Hyponatraemia: A Population-Based Study. *Am J Kidney Dis* 2013; 62: 67-
3 72.
- 4 106. Rosner MH. Severe Hyponatraemia Associated with the Combined Use of Thiazide
5 Diuretics and Selective Serotonin Reuptake Inhibitors. *Am J Med Sci* 2004; 327: 109-111.
- 6 107. Shapiro DS, Sonnenblick M, Galperin I, Melkonyan L, Munter G. Severe hyponatraemia in
7 elderly hospitalized patients: prevalence, aetiology and outcome. *Int Med J* 2010; 40:
8 574-580.
- 9 108. Sharabi Y, Illan R, Kamari Y, Cohen H, Nadler M, Messerli FH et al. Diuretic induced
10 hyponatraemia in elderly hypertensive women. *J Hum Hypertens* 2002; 16: 631-635.
- 11 109. Sonnenblick M, Rosin AJ. Significance of the measurement of uric acid fractional clearance
12 in diuretic induced hyponatraemia. *Postgrad Med J* 1986; 62: 449-452.
- 13 110. Sonnenblick M, Algur N, Rosin A. Thiazide-Induced Hyponatraemia and Vasopressin
14 Release. *An Int Med* 1989; 110: 751.
- 15 111. Takeshita M, Miyao M, Mizuno Y. Thiazide diuretics for hypertensive treatment induced
16 severe hyponatraemia with consciousness disturbance in two elderly cases. *Nippon*
17 *Ronen Igakkai Zasshi* 2010; 47: 257-261.
- 18 112. Tarssanen L, Huikko M, Rossi M. Amiloride-induced hyponatraemia. *Acta Med Scand*
19 1980; 208: 491-494.
- 20 113. Thuesen L, Frost JW. Hyponatraemia during thiazide therapy. *Ugeskrift for Laeger* 1980;
21 142: 1933-1934.
- 22 114. van Brummelen P, Schalekamp M, de Graeff J. Influence of sodium intake on
23 hydrochlorothiazide-induced changes in blood pressure, serum electrolytes, renin and
24 aldosterone in essential hypertension. *Acta Med Scand* 1978; 204: 151-157.

- 1 115. Van Wijngaarden T, Dekker J. Two confused patients. *Huisarts en Wetenschap* 2010; 53:
2 337-339.
- 3 116. Yong TY, Huang JE, Lau SY, Li JY. Severe hyponatremia and other electrolyte
4 disturbances associated with indapamide. *Curr Drug Saf.* 2011;6:134-7.
- 5 117. Zalin AM, Hutchinson CE, Jong M, Matthews K. Hyponatraemia during treatment with
6 chlorpropamide and Moduretic (amiloride plus hydrochlorothiazide). *BMJ (Clin Res Ed)*
7 1984; 289: 659.
- 8 118. Chow KM, Szeto CC, Wong TYH, Leung CB, Li PKT. Risk factors for thiazide-induced
9 hyponatraemia. *QJM* 2003; 96: 911-917.
- 10 119. Chow KM, Szeto CC, Kwan BCH, Ma TKW, Leung CB, Li PKT. Fracture risk after
11 thiazide-associated hyponatraemia. *Intern Med J* 2012; 42: 760-764.
- 12 120. Chow KM, Szeto CC, Kwan BCH, Li PKT. Influence of climate on the incidence of
13 thiazide-induced hyponatraemia. *Int J Clin Pract* 2007; 61: 449-452.
- 14 121. Clayton JA, Rodgers S, Blackey J, Avery A, Hall IP. Thiazide diuretic prescription and
15 electrolyte abnormalities in primary care. *Br J Clin Pharmacol* 2005; 61: 87-95.
- 16 122. McDowell SE, Thomas SK, Coleman JJ, Aronson JK, Ferner RE. A practical guide to
17 monitoring for adverse drug reactions during antihypertensive drug therapy. *J R Soc*
18 *Med* 2013; 106: 87-95.
- 19 123. McDowell SE, Ferner RE. Biochemical Monitoring of Patients Treated with
20 Antihypertensive Therapy for Adverse Drug Reactions. *Drug Safety* 2011; 34: 1049-1059.
- 21 124. Burton TJ, Salsbury J, Hood S, Brown MJ. Conn's syndrome unmasked by thiazide-induced
22 hypokalaemia. *Br J Hosp Med* 2011; 72: 530-531.
- 23 125. Lalioti M, Zhang J, olkman HM, ahle KT, offmann KE, oka HR et al. Wnk 4 controls blood
24 pressure and potassium homeostasis via regulation of mass and activity of the distal
25 convoluted tubule. *Nat Genet* 2006; 38: 1124-1132.

- 1 126. Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone.
2 Am J Med 1967; 42: 790-806.
- 3 127. Verlander JW, Tran TM, Zhang L, Kaplan MR, Hebert SC. Estradiol enhances thiazide-
4 sensitive NaCl cotransporter density in the apical plasma membrane of the distal
5 convoluted tubule in ovariectomized rats. J Clin Invest 1998; 101: 1661-1669.
- 6 128. ONS. Population Estimates for UK, England and Wales, Scotland and Northern Ireland -
7 mid 1991 to mid 2000. Available at [http://www.ons.gov.uk/ons/rel/pop-
8 estimate/population-estimates-for-uk--england-and-wales--scotland-and-northern-
9 ireland/mid-1991-to-mid-2000-local-authority-population-studies/index.html](http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-uk--england-and-wales--scotland-and-northern-ireland/mid-1991-to-mid-2000-local-authority-population-studies/index.html). Accessed
10 September 1, 2013.

11 **Figures**

12 **Figure 1:** Flow diagram of steps in systematic review in PRISMA format.

13 **Tables**

14 **Table 1:** Analysis of pooled data of the age, gender, BMI and duration of thiazide therapy of
15 patients with thiazide-induced hyponatraemia.

16 Body Mass Index (BMI), TIH (Thiazide Induced Hyponatraemia), Confidence Interval (CI), Pop
17 (Contributing population to the meta-analyses, number of studies/total number of patients with
18 the studies), Standard deviation (SD) and N (number of patients in single case reports). * Data
19 expressed as proportion

20
21 **Table 2:** Meta-analysis of the symptoms reported at presentation in patients with thiazide-
22 induced hyponatraemia.

23 Prevalence estimates from meta-analysis and confidence intervals are all expressed as
24 proportions. Prop (proportion), Pop (Contributing population to the meta-analyses, number of

1 studies/total number of patients with the studies), Confidence Interval (CI), N (number of single
2 case reports reporting the variable listed).

3
4 **Table 3:** Meta-analysis of the drug history in patients with thiazide-induced hyponatraemia.
5 Prevalence estimates from meta-analysis and confidence intervals are all expressed as
6 proportions of those studies that reported each given variable at least once.
7 HydroChloroThiaZide (HCTZ), AngioTensin Converting enzyme (ACE) inhibitor, Non-
8 Steroidal AntiInflammatory Drug (NSAID), Angiotensin Receptor Blocker (ARB), Prop
9 (proportion), Pop (Contributing population to the meta-analyses, number of studies/total number
10 of patients with the studies), Confidence Interval (CI), N (number of single case reports reporting
11 the variable listed).

12
13 **Table 4:** Meta-analysis of laboratory characteristics in patients with thiazide-induced
14 hyponatraemia.
15 Prevalence estimates from meta-analysis and confidence intervals are all expressed as
16 proportions. Confidence Interval (CI), N (number of single case reports reporting the variable
17 listed), Standard deviation (SD).

18
19
20
21
22
23